Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene profile for chemotherapy response in head and neck carcinoma

ABSTRACT: Transcriptional profiling was performed on biopsies from patients with head and neck squamous cell carcinoma that had been treated with cisplatin and 5-fluorouracil to identify genes predictive of response to chemotherapy

ORGANISM(S): Homo sapiens

PROVIDER: GSE32877 | GEO | 2013/10/06

SECONDARY ACCESSION(S): PRJNA146605

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene profile for chemotherapy response in head and neck carcinoma

Project description:Transcriptional profiling was performed on biopsies from patients with head and neck squamous cell carcinoma that had been treated with cisplatin and 5-fluorouracil to identify genes predictive of response to chemotherapy Two condition experiment, Biopsies from complete clinical responders and from non-responders were compared based upon a common reference using a two color design

2013-10-06 | E-GEOD-32877 | biostudies-arrayexpress

microRNA profiling for prediction of chemoradiation efficacy in locally advanced head and neck squamous cell carcinoma

Project description:The predictive value of microRNAs for the efficacy of chemoradiation (CRTX) in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated. Formalin-fixed, paraffin-embedded tumor material was collected from patients with locally advanced HNSCC treated within the ARO-0401 phase III trial with radiotherapy in combination with either 5-fluorouracil/cisplatin (CDDP-CRTX) or 5-fluorouracil/mitomycin C (MMC-CRTX).

2017-03-30 | E-MTAB-5198 | biostudies-arrayexpress

Definition of key mechanisms of multidrug resistance of head and neck tumors to chemo- and radiotherapy treatments. Identification of new individualized antitumor drugs (Ref. GC16173720CARR)

Project description:Head and neck squamous cell carcinoma (HNSCC) is the sixth most commonly diagnosed cancer worldwide, with an incidence of about 600,000 new cases per year, accounting for 1-2% of all cancer deaths worldwide. Current treatment for head and neck cancer includes taxol (docetaxel), platinum compounds (e.g. cisplatin or carboplatin) and the anti metabolite 5 fluorouracil (5 FU), either as single agents or in combination, and also radiotherapy. Response rates to these chemotherapeutic drugs range from 60 to 80%, however there are high rates of resistance, which often leads to locoregional recurrence and metastasis. The therapeutic dose of treatment needed (hormone therapy, radiotherapy or chemotherapy) is often too toxic for the patient to withstand. Therefore, our main objetive in this proyect is the identification of the molecular and cellular mechanisms involved in the acquisition of resistance to chemotherapy as currently key pieces for the discovery of new drugs that allow the development of effective therapies against HNSCC.

2020-11-12 | PXD020159 | Pride

Gene expression profiles of head and neck squamous cell carcinoma

Project description:Sage performed on microdissection of Head and Neck tumor, and Head and Neck normal tissue comparative analysis of gene expression profiles of head and neck squamous cell carcinoma and Head and Neck normal tissue

2008-09-30 | E-GEOD-11986 | biostudies-arrayexpress

Molecular subtypes of head and neck cancer – Prognostic impact and correlations with morphological characteristics

Project description:Aim Treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) are limited. Therefore, prognostic and predictive biomarkers for the application of personalized therapies are urgently needed.

2023-06-01 | GSE212070 | GEO

RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin

Project description:Human head and neck squamous cell carcinoma, SQD9 cells, were stable invalidated for TMEM45A using shRNA (Sigma). Then, transduced SQD9 cells were treated with 100 µM of cisplatin during 24h. All conditions were compared to untreated cells transduced with shRNA control (shCTL)(Sigma).

2020-03-04 | E-MTAB-7518 | biostudies-arrayexpress

Global miRNA expression profile of head and neck squamous cell carcinoma patients with resistant and sensitive tumors

Project description:The aim of the present study was to evaluate miRNAs as response predictors in FFPE head and neck samples from a phase II clinical trial designed to evaluate the feasibility of delivering cisplatin concurrent with radiotherapy after an induction chemotherapy (IC) regimen based on the combination of cisplatin plus paclitaxel in locally advanced head and neck squamous cell carcinoma (HNSCC) patients. For this purpose, we assessed the global miRNA expression profile of 15 HNSCC patients undergoing treatment, in order to identify miRNAs able to segregate resistant tumors from the sensitive ones, thus serving as markers to predict response. The results showed four miRNAs (miR-21, miR-494, miR-720 and miR-923) that were overexpressed in HNSCC FFPE samples.

2016-10-25 | E-MTAB-4854 | biostudies-arrayexpress

Suqamous Cell Carcinoma of Head and Neck

Project description:Gene Expression Analysis of Squamous Cell Carcinoma of Head and Neck Keywords: parallel sample

2005-12-14 | GSE2326 | GEO

Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer: normal head and neck tissue

Project description:Genome-wide DNA methylation profiling of head and neck squamous cell carcinomas. The Illumina Infinium 27k Human DNA methylation BeadChip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in fresh-frozen tumor tissues. Samples included 91 tumors from the oralpharynx and larynx, reflecting all stages of disease, 18 normal head and neck National Disease Research Interchange (NDRI) samples, and 213 normal control blood samples. Bisulphite-converted DNA from the 18 normal head and neck samples were hybridized to the Illumina Infinium 27k Human Methylation Beadchip v1.2.

2011-10-27 | E-GEOD-25083 | biostudies-arrayexpress